Literature DB >> 31462733

Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.

Nami Masubuchi1,2, Marito Araki3, Yinjie Yang1, Erina Hayashi1, Misa Imai1,4, Yoko Edahiro1, Yumi Hironaka1, Yoshihisa Mizukami1,5, Yoshihiko Kihara1,4, Hiraku Takei1, Mai Nudejima1, Masato Koike6, Akimichi Ohsaka3, Norio Komatsu7.   

Abstract

Studies have shown that mutant calreticulin (CALR) constitutively activates the thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of myeloproliferative neoplasms (MPNs). To further elucidate the molecular mechanism by which mutant CALR promotes MPN development, we studied the subcellular localization of mutant CALR and its importance for the oncogenic properties of mutant CALR. Here, mutant CALR accumulated in the Golgi apparatus, and its entrance into the secretion pathway and capacity to interact with N-glycan were required for its oncogenic capacity via the constitutive activation of MPL. Mutant CALR-dependent MPL activation was resistant to blockade of intracellular protein trafficking, suggesting that MPL is activated before reaching the cell surface. However, removal of MPL from the cell surface with trypsin shut down downstream activation, implying that the surface localization of MPL is required for mutant CALR-dependent activation. Furthermore, we found that mutant CALR and MPL interact on the cell surface. Based on these findings, we propose a model in which mutant CALR induces MPL activation on the cell surface to promote MPN development.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31462733     DOI: 10.1038/s41375-019-0564-z

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.

Authors:  Christian A Di Buduo; Vittorio Abbonante; Caroline Marty; Francesco Moccia; Elisa Rumi; Daniela Pietra; Paolo M Soprano; Dmitry Lim; Daniele Cattaneo; Alessandra Iurlo; Umberto Gianelli; Giovanni Barosi; Vittorio Rosti; Isabelle Plo; Mario Cazzola; Alessandra Balduini
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

Review 2.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

3.  Impact of Calreticulin and Its Mutants on Endoplasmic Reticulum Function in Health and Disease.

Authors:  Najla Arshad; Peter Cresswell
Journal:  Prog Mol Subcell Biol       Date:  2021

4.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

5.  Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Authors:  Krzysztof Lewandowski; Zuzanna Kanduła; Michał Gniot; Edyta Paczkowska; Paulina Maria Nawrocka; Marzena Wojtaszewska; Michał Janowski; Magdalena Mariak; Luiza Handschuh; Piotr Kozlowski
Journal:  Ann Hematol       Date:  2022-10-21       Impact factor: 4.030

6.  MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

Authors:  Shunichiro Yasuda; Satoru Aoyama; Ryoto Yoshimoto; Huixin Li; Daisuke Watanabe; Hiroki Akiyama; Kouhei Yamamoto; Takeo Fujiwara; Yuho Najima; Noriko Doki; Emiko Sakaida; Yoko Edahiro; Misa Imai; Marito Araki; Norio Komatsu; Osamu Miura; Norihiko Kawamata
Journal:  Int J Hematol       Date:  2021-06-24       Impact factor: 2.490

Review 7.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

Review 8.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

9.  Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers.

Authors:  Arunkumar Venkatesan; Jie Geng; Malathi Kandarpa; Sanjeeva Joseph Wijeyesakere; Ashwini Bhide; Moshe Talpaz; Irina D Pogozheva; Malini Raghavan
Journal:  J Cell Biol       Date:  2021-07-05       Impact factor: 10.539

Review 10.  Pathogenic Effects of Impaired Retrieval between the Endoplasmic Reticulum and Golgi Complex.

Authors:  Hiroshi Kokubun; Hisayo Jin; Tomohiko Aoe
Journal:  Int J Mol Sci       Date:  2019-11-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.